20n Bio (pr. "twenty-n bio") is a VC-backed startup dedicated to discovering cyclic peptides for therapeutic use. Based in the Greater Philadelphia region, 20n Bio's mission is to address unmet medical needs by leveraging high-throughput screening and chemical optimization to develop peptide drugs across various therapeutic areas.

Our Focus

Peptides offer the best of both small molecules and antibodies, demonstrating significant therapeutic potential across a wide range of modalities, including oral peptides, radioligand therapy, peptide-drug conjugates, etc. Their versatility enables them to target diverse biological pathways, making them suitable for treating conditions from metabolic disorders to complex cancers. Peptides also generally exhibit high specificity and affinity for their targets, resulting in fewer off-target effects and improved safety compared to traditional small molecules.

While most FDA-approved peptide drugs are natural derivatives, advancements in de novo peptide discovery are addressing challenges such as the vast sequence space and the optimization of peptides for stability and bioavailability. Emerging technologies are making it increasingly feasible to identify peptides with desired therapeutic activity.

20n Bio has developed a proprietary peptide discovery platform capable of screening libraries containing trillions of peptides at once, offering unparalleled potential to identify the most potent candidates. By utilizing high-throughput screening, the platform efficiently navigates the immense peptide sequence space to quickly identify peptides with optimal binding and therapeutic properties. This ability to discover high-affinity peptides de novo opens new avenues for developing innovative treatments to address unmet medical needs.

In addition to internal pipeline development, 20n Bio is also dedicated to partnering with pharmaceutical and biotechnology companies, providing customized solutions to help bring novel peptide therapeutics to market efficiently. As the demand for targeted and effective therapies continues to grow, 20n Bio is at the forefront of peptide innovation, driving advancements that are shaping the future of modern medicine.

Leadership Team

We are a group of peptide believers. 

We encourage enthusiastic scientists to join us to fulfill our mission.

Company News

Jan 31, 2024: 20n Bio Appoints Linghang Zhuang, Ph.D., as President, to lead the discovery of cyclic peptide drugs.

Dec 17, 2021: 20n Bio 20n Bio Raises $3.3 Million in Series Seed Funding.